Notizia - Recent Pharma, Healthcare and Biotech Happenings

Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, Nivolumab (Opdivo) is ready to become the new standard-of-care option for all platinum-refractory patients with head and neck cancer, as per the recent findings. The PD-L1 inhibitor has received a priority review designation by the FDA in July 2016 based on the CheckMate-141 study, as presented in the ASCO 2016 Annual Meeting. R...